Shanghai Curegene Pharmaceutical Co. Ltd. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infections (COVID-19).
Researchers from Universidade Estadual da Paraíba, Universidade Federal da Paraiba and affiliated organizations presented the design, synthesis and bio-evaluation of new small-molecule candidates for the treatment of leishmaniasis, a neglected tropical disease that affects approximately 12 million people in four continents.
Scientists at the University of Pittsburgh have tested a broadly neutralizing antibody that binds the stem of a protein against H5N1 avian influenza, which prevented severe disease in nonhuman primates and was effective for at least 8 weeks. The scientists remark on the potential of the design developed by Astrazeneca plc against a possible outbreak of the influenza A virus.
Chugai Pharmaceutical Co. Ltd. has signed a collaboration agreement with GSK plc’s Global Health Unit (GSK GH) for the development of an anti-dengue virus antibody. Under this agreement, GSK GH will perform activities and explore potential funding for the initiation of clinical studies of AID-351.
Multiple organ dysfunction syndrome is a life-threatening condition derived from heat stress or sepsis, among other conditions, that can lead to irreversible organ damage and death if left untreated. Gasdermin (GSDMD) is an executor protein that causes cell lysis, facilitates the release of inflammatory mediators and is involved in pyroptosis, apoptosis and necroptosis processes leading to inflammatory cell death or PANoptosis.
Ebola virus and Marburg virus are single-stranded, enveloped and negative sense-RNA viruses belonging to the Filoviridae family, and they both cause deadly hemorrhagic fevers in humans and mammals.
Over-colonization and subsequent inflammation triggered by Cutibacterium acnes is the primary factor in the pathogenesis of acne vulgaris, a prevalent skin condition among adolescents. Gyeongsang National University has discovered and characterized new antimicrobial peptides (AMPs) as candidates for the treatment of acne vulgaris.
Ocugen Inc. has received IND clearance from the FDA for OCU-500, an inhaled mucosal vaccine for COVID-19. The National Institute of Allergy and Infectious Diseases (NIAID) will sponsor and conduct a phase I trial of OCU-500 administered via inhalation into the lungs and intranasally as a spray.
Pseudomonas aeruginosa is included in the World Health Organization’s Bacterial Priority Pathogen List 2024 because of its concerning ability to acquire and develop high levels of antimicrobial resistance. New-in-class antimicrobial options specifically targeting multidrug-resistant (MDR) P. aeruginosa are lacking.
RSS
